Evidence map›Paper›PMID 40044429›Full record

ReviewZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2025

[Research progress in the extent of hepatocellular carcinoma in the year 2024].

Y M Nan, T G Miao, S X Zhao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Y M NanDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital & Department of Gastroenterology, Hebei Medical University Third Hospital, Shijiazhuang 050051, China Hebei Provincial Key Laboratory of Liver Fibrosis Mechanism Study in Chronic Liver Diseases & Hebei International Joint Research Center for Liver Cancer Molecular Diagnosis, Hebei International Science and Technology Cooperation Base, Shijiazhuang 050051, China.
T G MiaoDepartment of Hepato-Gastroenterology, Tianjin First Central Hospital, Tianjin 300190, China.
S X ZhaoDepartment of Traditional and Western Medical Hepatology, Hebei Medical University Third Hospital & Department of Gastroenterology, Hebei Medical University Third Hospital, Shijiazhuang 050051, China Hebei Provincial Key Laboratory of Liver Fibrosis Mechanism Study in Chronic Liver Diseases & Hebei International Joint Research Center for Liver Cancer Molecular Diagnosis, Hebei International Science and Technology Cooperation Base, Shijiazhuang 050051, China.

Funding

Hebei Province Medical Application Technology Tracking Project GZ2024048Key Research and Development Plan Projects of Hebei Province 23377705DThe Introduction of Foreign Intelligence Program in Hebei Province 2024
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsChinaDrug Resistance, NeoplasmHumansNeoplasm Metastasis

Identifiers

PMID40044429
PMCPMC12899217

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.